<DOC>
	<DOC>NCT01018238</DOC>
	<brief_summary>This trial is conducted in the United States of America (USA). The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetics and signs of bioactivity of increasing repeated doses of NNC 151-0000-0000 in subjects with Systemic Lupus Erythematosus (SLE).</brief_summary>
	<brief_title>An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)</brief_title>
	<detailed_description>The trial was terminated before any patients were exposed to the trial drug based on new findings indicating that dose escalation with multiple doses should be performed in a different trial population.</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>Diagnosis of systemic lupus erythematosus (SLE) Disease duration: 6 months or longer Stable, mild to moderately active systemic lupus erythematosus (SLE) Receiving stable maintenance therapy Significant Lupus Nephritis Active central nervous system (CNS) disease Significant arterial or venous thrombosis (blood clots) within 12 months prior to trial start Body weight of 260 lbs/120 kg or more History of alcohol or substance abuse History of cancer Infections Viral infections: HIV, Hepatitis B or C, EpsteinBarr Virus (EBV), Cytomegalovirus (CMV), VaricellaZoster Virus (VZV), or Herpes Simplex Virus (HSV1 or HSV2) Tuberculosis Severe systemic bacterial, viral or fungal infections within the past 12 months prior to trial start Immunosuppressive and immune modulating therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>